Biotech Valuation - Valuation Services

Testimonials

Galecto IPO

NASDAQ: GLTO | $85M raised | October 28, 2020

“Thanks to the tireless efforts of the Danforth team, we were able to complete a crossover financing and price our IPO within 90 days of the organizational meeting. It wouldn’t have been possible without their support and critical role in the S-1 drafting process, SEC correspondence and countless other areas.”

Jon Freve, CFO, Galecto
Gemini Therapeutics SPAC Offering

NASDAQ: GMTX | $216M raised | February 5, 2021

“The Danforth team has been instrumental to our financing strategy and execution, including the leadership of Gregg Beloff as CFO and the expert handling of technical and operational accounting that made this transaction possible.”

Jason Meyenburg, CEO, Gemini Therapeutics
Graybug Vision IPO

NASDAQ: GRAY | $90M raised | Upsized by 20% | September 24, 2020

“I can’t overstate the impact of Danforth’s contributions to this accomplishment and the work that preceded it. From Daniel Geffken’s leadership as interim CFO through the team’s detailed preparation and execution, they got it done to the highest of standards.”

Fred Guerard, CEO, Graybug Vision
Lysosomal Therapeutics Acquisition

Acquired by BIAL Pharmaceuticals | October 1, 2020

“This is a tremendous outcome for Lysosomal, and Danforth was instrumental to the journey from start to finish, having built and led our finance function for the past seven years. Their efforts to close this deal, particularly the work of consultant Cheryl McCarthy, were nothing short of heroic.”

Clay Thorp, Board Member, Lysosomal Therapeutics
Pandion Therapeutics IPO

NASDAQ: PAND | $135M raised | Upsized by 36%, priced at peak of range | July 17, 2020

“The IPO was a huge achievement for Pandion. Thank you to the Danforth team for all of your expertise, support and guidance – tireless and dogged in making sure we got here.”

Rahul Kakkar, CEO, Pandion Therapeutics
Zikani Therapeutics Acquisition

Acquired by ELOXX Pharmaceuticals | April 1, 2021

“We are thankful to Daniel Geffken and the Danforth team who supported our operational foundation from the earliest stages through this important milestone. We are pleased to have Daniel on the team during this important integration period and, with his continued support, we are well equipped to advance as a combined entity in the development of novel genetic therapies for rare diseases and rare cancers.”

Sumit Aggarwal, President and CEO, Zikani Therapeutics

Stay informed

Subscribe to our newsletter for updates, events and insights

Subscribe Now